Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 305

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 14
Chunk 305
---
ewith, with the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said
attorney to any and all amendments to said Report.

Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on
behalf of the Registrant in the capacities and on the dates indicated.

    Name
     
    Title
     
    Date

    /s/
    Jeffrey A. Meckler
     
    Chief Executive Officer
    and Director
     
    March
    13, 2025
  
    Jeffrey
    A. Meckler
     
    (Principal Executive Officer)

    /s/
    Nir Sassi
     
    Chief Financial Officer
     
    March
    13, 2025
  
    Nir
    Sassi
     
    (Principal Financial and
    Accounting Officer)

    /s/
    Michal J. Newman, Ph.D.
     
    Chief
    Scientific Officer and Director
     
    March
    13, 2025
  
    Michael
    J. Newman, Ph.D.

    /s/
    Roger J. Pomerantz, M.D.
     
    Chairman
    of the Board of Directors
     
    March
    13, 2025
  
    Dr.
    Roger J. Pomerantz, M.D.

    /s/
    Hila Karah
     
    Director
     
    March
    13, 2025
  
    Hila
    Karah

    /s/
    Anthony J. Maddaluna
     
    Director
     
    March
    13, 2025
  
    Anthony
    J. Maddaluna

    /s/
    Mark J. Gilbert
     
    Director
     
    March
    13, 2025
  
    Mark
    J. Gilbert

    /s/
    William B. Hayes
     
    Director
     
    March
    13, 2025
  
    William
    B. Hayes

    /s/
    Robert E. Martell, M.D., Ph.D.
     
    Director
     
    March
    13, 2025
  
    Robert
    E. Martell, M.D., Ph.D.

97